vs
Side-by-side financial comparison of Adaptive Biotechnologies Corp (ADPT) and Revolution Medicines, Inc. (RVMD). Click either name above to swap in a different company.
Adaptive Biotechnologies Corp produced more free cash flow last quarter ($1.4M vs $-139.5M). Over the past eight quarters, Adaptive Biotechnologies Corp's revenue compounded faster (30.8% CAGR vs -100.0%).
ExpreS2ion Biotechnologies is a Danish biotechnology company specialised in the development of new vaccines and immunotherapy products based in Hørsholm, Denmark and listed on the Nasdaq First North Growth Market Sweden.
Tempus AI, Inc. is an American health technology company founded in 2015 by Eric Lefkofsky in Chicago, Illinois. It was established by Lefkofsky soon after his wife was diagnosed with breast cancer. Tempus uses data and artificial intelligence (AI) to create precision medicine services, including diagnostics, for oncology, cardiology, radiology, and depression. The company went public on the Nasdaq on June 14, 2024, under the ticker symbol "TEM."
ADPT vs RVMD — Head-to-Head
Income Statement — Q4 2025 vs Q4 2024
| Metric | | |
|---|---|---|
| Revenue | $71.7M | $0 |
| Net Profit | $-13.6M | $-194.6M |
| Gross Margin | 74.6% | — |
| Operating Margin | -17.8% | — |
| Net Margin | -18.9% | — |
| Revenue YoY | 51.0% | — |
| Net Profit YoY | 59.7% | -20.4% |
| EPS (diluted) | $-0.08 | $-1.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $71.7M | — | ||
| Q3 25 | $94.0M | — | ||
| Q2 25 | $58.9M | — | ||
| Q1 25 | $52.4M | — | ||
| Q4 24 | $47.5M | $0 | ||
| Q3 24 | $46.4M | $0 | ||
| Q2 24 | $43.2M | $0 | ||
| Q1 24 | $41.9M | $0 |
| Q4 25 | $-13.6M | — | ||
| Q3 25 | $9.5M | — | ||
| Q2 25 | $-25.6M | — | ||
| Q1 25 | $-29.9M | — | ||
| Q4 24 | $-33.7M | $-194.6M | ||
| Q3 24 | $-32.1M | $-156.3M | ||
| Q2 24 | $-46.2M | $-133.2M | ||
| Q1 24 | $-47.5M | $-116.0M |
| Q4 25 | 74.6% | — | ||
| Q3 25 | 80.7% | — | ||
| Q2 25 | 69.4% | — | ||
| Q1 25 | 67.6% | — | ||
| Q4 24 | 62.0% | — | ||
| Q3 24 | 64.1% | — | ||
| Q2 24 | 55.3% | — | ||
| Q1 24 | 56.9% | — |
| Q4 25 | -17.8% | — | ||
| Q3 25 | 10.9% | — | ||
| Q2 25 | -42.5% | — | ||
| Q1 25 | -56.4% | — | ||
| Q4 24 | -71.3% | — | ||
| Q3 24 | -70.3% | — | ||
| Q2 24 | -109.6% | — | ||
| Q1 24 | -116.5% | — |
| Q4 25 | -18.9% | — | ||
| Q3 25 | 10.2% | — | ||
| Q2 25 | -43.5% | — | ||
| Q1 25 | -56.9% | — | ||
| Q4 24 | -71.0% | — | ||
| Q3 24 | -69.1% | — | ||
| Q2 24 | -107.0% | — | ||
| Q1 24 | -113.5% | — |
| Q4 25 | $-0.08 | — | ||
| Q3 25 | $0.06 | — | ||
| Q2 25 | $-0.17 | — | ||
| Q1 25 | $-0.20 | — | ||
| Q4 24 | $-0.22 | $-1.13 | ||
| Q3 24 | $-0.22 | $-0.94 | ||
| Q2 24 | $-0.31 | $-0.81 | ||
| Q1 24 | $-0.33 | $-0.70 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $70.5M | $2.3B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $218.8M | $2.3B |
| Total Assets | $512.7M | $2.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $70.5M | — | ||
| Q3 25 | $55.0M | — | ||
| Q2 25 | $43.2M | — | ||
| Q1 25 | $50.6M | — | ||
| Q4 24 | $47.9M | $2.3B | ||
| Q3 24 | $38.1M | $1.5B | ||
| Q2 24 | $59.8M | $1.6B | ||
| Q1 24 | $71.2M | $1.7B |
| Q4 25 | $218.8M | — | ||
| Q3 25 | $204.4M | — | ||
| Q2 25 | $179.7M | — | ||
| Q1 25 | $190.4M | — | ||
| Q4 24 | $202.7M | $2.3B | ||
| Q3 24 | $223.8M | $1.6B | ||
| Q2 24 | $241.6M | $1.6B | ||
| Q1 24 | $274.9M | $1.7B |
| Q4 25 | $512.7M | — | ||
| Q3 25 | $490.6M | — | ||
| Q2 25 | $496.6M | — | ||
| Q1 25 | $510.9M | — | ||
| Q4 24 | $539.4M | $2.6B | ||
| Q3 24 | $558.5M | $1.8B | ||
| Q2 24 | $584.9M | $1.8B | ||
| Q1 24 | $620.3M | $1.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.1M | $-138.3M |
| Free Cash FlowOCF − Capex | $1.4M | $-139.5M |
| FCF MarginFCF / Revenue | 2.0% | — |
| Capex IntensityCapex / Revenue | 0.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-48.9M | $-567.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.1M | — | ||
| Q3 25 | $-7.1M | — | ||
| Q2 25 | $-12.4M | — | ||
| Q1 25 | $-28.5M | — | ||
| Q4 24 | $-12.5M | $-138.3M | ||
| Q3 24 | $-27.1M | $-130.4M | ||
| Q2 24 | $-17.3M | $-128.2M | ||
| Q1 24 | $-38.4M | $-160.6M |
| Q4 25 | $1.4M | — | ||
| Q3 25 | $-7.5M | — | ||
| Q2 25 | $-13.1M | — | ||
| Q1 25 | $-29.7M | — | ||
| Q4 24 | $-12.6M | $-139.5M | ||
| Q3 24 | $-27.4M | $-133.9M | ||
| Q2 24 | $-19.0M | $-130.6M | ||
| Q1 24 | $-39.9M | $-163.7M |
| Q4 25 | 2.0% | — | ||
| Q3 25 | -8.0% | — | ||
| Q2 25 | -22.2% | — | ||
| Q1 25 | -56.7% | — | ||
| Q4 24 | -26.5% | — | ||
| Q3 24 | -59.0% | — | ||
| Q2 24 | -44.1% | — | ||
| Q1 24 | -95.2% | — |
| Q4 25 | 0.9% | — | ||
| Q3 25 | 0.4% | — | ||
| Q2 25 | 1.1% | — | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.7% | — | ||
| Q2 24 | 4.0% | — | ||
| Q1 24 | 3.6% | — |
| Q4 25 | — | — | ||
| Q3 25 | -0.75× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADPT
| Mrd Business Segment | $61.9M | 86% |
| Immune Medicine Business | $9.8M | 14% |
| Immune Medicine Service Revenue | $100.0K | 0% |
RVMD
Segment breakdown not available.
